Study: Merck and Daiichi’s Lung Cancer Treatment Shows Promise
ZacksMRK and Daiichi Sankyo’s patritumab deruxtecan shows statistically significant progression-free survival improvement in previously treated EGFR-mutated NSCLC.
MRK and Daiichi Sankyo’s patritumab deruxtecan shows statistically significant progression-free survival improvement in previously treated EGFR-mutated NSCLC.